International Congress of Parkinson’s Disease and Movement Disorders® 2025

📢🔬 Lys Therapeutics is proud to announce new efficacy data in #Parkinson‘s at the International Congress of Parkinson’s Disease and Movement Disorders® 2025 organized by the International Parkinson and Movement Disorder Society.

#Efficacy and proof-of-concept preclinical data of Lys Therapeutics’ monoclonal antibody #LYS241 selected for #oral presentation at the world major congress on Parkinson’s disease, October 6, 2025, in Honolulu, Hawaii, US.

Abstract #835: A Novel Therapeutic Targeting the tPA-NMDAr Interaction for Parkinson’s Disease

Date/Time: Monday, October 6, 12:30-13:30

Oral Platform Presentation OPP 03: Parkinson’s Disease – Surgical Therapy and Other

Location: Room 313A

We are honored to share this work conducted in collaboration with the University of Michigan (Prof. Daniel Lawrence, Dr. Daniel Torrente) and supported by the The Michael J. Fox Foundation for Parkinson’s Research.

—

#MDSCongress #MDSCongress2025 #Parkinson #NeurodegenerativeDisorders #Neuroscience #CNS #Patients #research #healthcare #drug #therapeutics #antibody #biotech #LysTherapeutics